NOTICE: Due to a lapse in annual appropriations, most of this website is not being updated. Learn more.
Form submissions will still be accepted but will not receive responses at this time. Sections of this site for programs using non-appropriated funds (such as NVLAP) or those that are excepted from the shutdown (such as CHIPS and NVD) will continue to be updated.
An official website of the United States government
Here’s how you know
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Engineering Receptor-Mediated Cytotoxicity Into Human Ribonucleases by Steric Blockade of Inhibitor Interaction
Published
Author(s)
M Suzuki, S K. Saxena, E Boix, R J. Prill, V M. Vasandani, Jane E. Ladner, C Sung, R J. Youle
Abstract
Several nonammalian members of the Rnase A superfamily exhibit anticancer activity that appears to correlate with resistance to the cytosolic ribonuclease inhibitor (RI). We mutated two human ribonucleases-pancreatic Rnase (hRNAse) and eosinophil-derived neurotoxin (EDN)-to incorporate cysteine residues at putative sites of close contact to RI, but distant from the catalytic sites. Coupling of Cys89 of Rnase and Cys87 of EDN to proteins at these sites via a thioether bond produced enzymatically active conjugates that were resistant to RI. To elicit cellular targeting as well as to block RI binding, transferrin was conjugated to a mutant human Rnase, rh Rnase (Gly89->Cys) and a mutant EDN (Thr87->Cys). The transferrin-rhRNase(Gly89->Cys)thioether conjugate was 5000-fold more toxic to U251 cells than recombinant wild-type hRNase. In addition, transferrin-targeted EDN exhibited tumor cell toxicities similar to those of hRNase. Thus, we endowed two human RI-sensitive Rnases with greater cytotoxicity by increasing their resistance to RI. This strategy has the potential to generate a novel set of recombinant human proteins useful for targeted therapy of cancer.
Suzuki, M.
, Saxena, S.
, Boix, E.
, Prill, R.
, Vasandani, V.
, Ladner, J.
, Sung, C.
and Youle, R.
(1999),
Engineering Receptor-Mediated Cytotoxicity Into Human Ribonucleases by Steric Blockade of Inhibitor Interaction, Nature Biotechnology
(Accessed October 11, 2025)